TABLE OF CONTENTS
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Cellulite Type
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Impact on Supply Chain
5.3.3. Regional Impact
5.3.4. Opportunity and Threat Analysis
6. GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT
6.1. Overview
6.2. Glucose Monitoring
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.2.1. Strips
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.2.2. Meters
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.2.3. Lancets
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.3. Cardiometabolic Monitoring
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.3.1. Cardiac Marker Testing Products
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.3.2. Blood Gas/Electrolyte Testing Products
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.3.3. HbA1c Testing Products
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.4. Infectious Disease Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.4.1. HIV Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.4.2. Respiratory Infection Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.4.3. Hepatitis Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.4.4. Sexually Transmitted Disease Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.4.5. Others
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.5. Coagulation Monitoring
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.5.1. PT/INR Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.5.2. ACT/APTT Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.6. Pregnancy & Fertility Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.7. Hematology Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.8. Cancer/Tumor Marker Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.9. Urinalysis Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.10. Cholesterol
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.11. Drugs-of-Abuse Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.12. Others
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
7. GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER
7.1. Overview
7.2. Hospitals & Clinics
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
7.3. Diagnostic Centers
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
7.4. Homecare/Self Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
7.5. Others
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
8. GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE
8.1. Overview
8.2. OTC Testing Products
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
8.3. Prescription-based testing products
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
9. GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM
9.1. Overview
9.2. Immunoassays
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
9.3. Dipsticks
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
9.4. Molecular Diagnostics
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
9.5. Others
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
10. GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY REGION
10.1. Overview
10.2. North America
10.2.1. US
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. UK
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. India
10.4.3. Japan
10.4.4. South Korea
10.4.5. Australia
10.4.6. Rest of Asia-Pacific
10.5. Rest of the World
10.5.1. Middle East
10.5.2. Africa
10.5.3. Latin America
11. COMPANY LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Global Point of Care Diagnostics/Testing Market
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Global Point of Care Diagnostics/Testing Market
11.7. Key developments and Growth Strategies
11.7.1. New ProductLaunch/Service Deployment
11.7.2. Merger &Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales & Operating Income, 2020
11.8.2. Major Players R&D Expenditure, 2020
12. COMPANY PROFILES
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Product Offered
12.1.3. Financial Overview
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Siemens Healthineers GmbH
12.2.1. Company Overview
12.2.2. Product Offered
12.2.3. Financial Overview
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Chembio Diagnostics, Inc.
12.3.1. Company Overview
12.3.2. Product Offered
12.3.3. Financial Overview
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. F. Hoffmann-La Roche Ltd
12.4.1. Company Overview
12.4.2. Product Offered
12.4.3. Financial Overview
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Johnson & Johnson Services, Inc.
12.5.1. Company Overview
12.5.2. Product Offered
12.5.3. Financial Overview
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. Becton, Dickinson and Company
12.6.1. Company Overview
12.6.2. Product Offered
12.6.3. Financial Overview
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. Danaher Corporation
12.7.1. Company Overview
12.7.2. Product Offered
12.7.3. Financial Overview
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. PTS Diagnostics
12.8.1. Company Overview
12.8.2. Product Offered
12.8.3. Financial Overview
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. Nova Biomedical
12.9.1. Company Overview
12.9.2. Product Offered
12.9.3. Financial Overview
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. Quidel Corporation
12.10.1. Company Overview
12.10.2. Product Offered
12.10.3. Financial Overview
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
12.11. Sekisui Diagnostics
12.11.1. Company Overview
12.11.2. Product Offered
12.11.3. Financial Overview
12.11.4. Key Developments
12.11.5. SWOT Analysis
12.11.6. Key Strategies
12.12. Trinity Biotech
12.12.1. Company Overview
12.12.2. Product Offered
12.12.3. Financial Overview
12.12.4. Key Developments
12.12.5. SWOT Analysis
12.12.6. Key Strategies
12.13. AccuBioTech Co., Ltd.
12.13.1. Company Overview
12.13.2. Product Offered
12.13.3. Financial Overview
12.13.4. Key Developments
12.13.5. SWOT Analysis
12.13.6. Key Strategies
12.14. Instrumentation Laboratory Company (Werfen)
12.14.1. Company Overview
12.14.2. Product Offered
12.14.3. Financial Overview
12.14.4. Key Developments
12.14.5. SWOT Analysis
12.14.6. Key Strategies
12.15. EKF Diagnostics Holdings plc
12.15.1. Company Overview
12.15.2. Product Offered
12.15.3. Financial Overview
12.15.4. Key Developments
12.15.5. SWOT Analysis
12.15.6. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET SYNOPSIS, 2022–2030
TABLE 2 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET ESTIMATES &FORECAST, 2022–2030(USD MILLION)
TABLE 3 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BYPRODUCT, 2022–2030 (USD MILLION)
TABLE 4 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER,2022–2030 (USD MILLION)
TABLE 5 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 6 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 7 NORTH AMERICA OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 8 NORTH AMERICAPOINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER,2022–2030 (USD MILLION)
TABLE 9 NORTH AMERICAPOINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 10 NORTH AMERICAPOINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 11 US: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 12 US POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 13 US: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 14 US: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 15 CANADA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 16 CANADA POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 17 CANADA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 18 CANADA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 19 EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 20 EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 21 EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 22 EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 23 GERMANY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 24 GERMANY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 25 GERMANY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 26 GERMANY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 27 FRANCE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 28 FRANCE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 29 FRANCE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 30 FRANCE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 31 UK: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 32 UK: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 33 UK: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 34 UK: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 35 ITALY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 36 ITALY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER2022–2030 (USD MILLION)
TABLE 37 ITALY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 38 ITALY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 39 SPAIN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 40 SPAIN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 41 SPAIN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 42 SPAIN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BYPLATFORM2022–2030 (USD MILLION)
TABLE 43 REST OF EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 44 REST OF EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 45 REST OF EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 46 REST OF EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 47 ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 48 ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 49 ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 50 ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 51 CHINA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 52 CHINA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 53 CHINA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 54 CHINA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 55 INDIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 56 INDIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 57 INDIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 58 INDIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 59 JAPAN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 60 JAPAN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 61 JAPAN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 62 JAPAN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 63 SOUTH KOREA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 64 SOUTH KOREA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 65 SOUTH KOREA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 66 SOUTH KOREA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 67 AUSTRALIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 68 AUSTRALIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 69 AUSTRALIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 70 AUSTRALIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 71 REST OF ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 72 REST OF ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 73 REST OF ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 74 REST OF ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 75 REST OF WORLD: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 76 REST OF WORLD: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 77 REST OF WORLD: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 78 REST OF WORLD: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 79 MIDDLE EAST: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 80 MIDDLE EAST: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 81 MIDDLE EAST: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 82 MIDDLE EAST: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 83 AFRICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 84 AFRICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 85 AFRICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 86 AFRICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
TABLE 87 LATIN AMERICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
TABLE 88 LATIN AMERICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 89 LATIN AMERICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
TABLE 90 LATIN AMERICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL POINT OF CAREDIAGNOSTICS/TESTING MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET
FIGURE 4 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PRODUCT, 2020 (%)
FIGURE 5 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY END USER, 2020 (%)
FIGURE 6 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
FIGURE 7 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PLATFORM, 2020 (%)
FIGURE 8 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY REGION, 2020 (%)
FIGURE 9 NORTH AMERICAPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PRODUCT, 2020 (%)
FIGURE 10 NORTH AMERICAPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY END USER, 2020 (%)
FIGURE 11 NORTH AMERICAPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
FIGURE 12 NORTH AMERICAPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PLATFORM, 2020 (%)
FIGURE 13 EUROPEPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PRODUCT, 2020 (%)
FIGURE 14 EUROPEPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY END USER, 2020 (%)
FIGURE 15 EUROPEPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
FIGURE 16 EUROPEPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PLATFORM, 2020 (%)
FIGURE 17 ASIA-PACIFICPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PRODUCT, 2020 (%)
FIGURE 18 ASIA-PACIFICPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY END USER, 2020 (%)
FIGURE 19 ASIA-PACIFICPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
FIGURE 20 ASIA-PACIFICPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PLATFORM, 2020 (%)
FIGURE 21 REST OF THE WORLDPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PRODUCT, 2020 (%)
FIGURE 22 REST OF THE WORLD POINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY END USER, 2020 (%)
FIGURE 23 REST OF THE WORLDPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
FIGURE 24 REST OF THE WORLD POINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PLATFORM, 2020 (%)
FIGURE 25 ABBOTT LABORATORIES .: KEY FINANCIALS
FIGURE 26 ABBOTT LABORATORIES : SEGMENTAL REVENUE
FIGURE 27 ABBOTT LABORATORIES : REGIONAL REVENUE
FIGURE 28 SIEMENS HEALTHINEERS GMBH : KEY FINANCIALS
FIGURE 29 SIEMENS HEALTHINEERS GMBH : SEGMENTAL REVENUE
FIGURE 30 SIEMENS HEALTHINEERS GMBH : REGIONAL REVENUE
FIGURE 31 CHEMBIO DIAGNOSTICS, INC. : KEY FINANCIALS
FIGURE 32 CHEMBIO DIAGNOSTICS, INC. : SEGMENTAL REVENUE
FIGURE 33 CHEMBIO DIAGNOSTICS, INC. : REGIONAL REVENUE
FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: KEY FINANCIALS
FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: SEGMENTAL REVENUE
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: REGIONAL REVENUE
FIGURE 37 JOHNSON & JOHNSON SERVICES, INC. : KEY FINANCIALS
FIGURE 38 JOHNSON & JOHNSON SERVICES, INC. : SEGMENTAL REVENUE
FIGURE 39 JOHNSON & JOHNSON SERVICES, INC. : REGIONAL REVENUE
FIGURE 40 BECTON, DICKINSON AND COMPANY : KEY FINANCIALS
FIGURE 41 BECTON, DICKINSON AND COMPANY : SEGMENTAL REVENUE
FIGURE 42 BECTON, DICKINSON AND COMPANY : REGIONAL REVENUE
FIGURE 43 DANAHER CORPORATION : KEY FINANCIALS
FIGURE 44 DANAHER CORPORATION : SEGMENTAL REVENUE
FIGURE 45 DANAHER CORPORATION : REGIONAL REVENUE
FIGURE 46 PTS DIAGNOSTICS: KEY FINANCIALS
FIGURE 47 PTS DIAGNOSTICS: SEGMENTAL REVENUE
FIGURE 48 PTS DIAGNOSTICS: REGIONAL REVENUE
FIGURE 49 NOVA BIOMEDICAL : KEY FINANCIALS
FIGURE 50 NOVA BIOMEDICAL : SEGMENTAL REVENUE
FIGURE 51 NOVA BIOMEDICAL : REGIONAL REVENUE
FIGURE 52 QUIDEL CORPORATION : KEY FINANCIALS
FIGURE 53 QUIDEL CORPORATION : SEGMENTAL REVENUE
FIGURE 54 QUIDEL CORPORATION : REGIONAL REVENUE
FIGURE 55 SEKISUI DIAGNOSTICS : KEY FINANCIALS
FIGURE 56 SEKISUI DIAGNOSTICS : SEGMENTAL REVENUE
FIGURE 57 SEKISUI DIAGNOSTICS : REGIONAL REVENUE
FIGURE 58 TRINITY BIOTECH : KEY FINANCIALS
FIGURE 59 TRINITY BIOTECH : SEGMENTAL REVENUE
FIGURE 60 TRINITY BIOTECH : REGIONAL REVENUE
FIGURE 61 ACCUBIOTECH CO., LTD.: KEY FINANCIALS
FIGURE 62 ACCUBIOTECH CO., LTD.: SEGMENTAL REVENUE
FIGURE 63 ACCUBIOTECH CO., LTD.: REGIONAL REVENUE
FIGURE 64 INSTRUMENTATION LABORATORY COMPANY (WERFEN): KEY FINANCIALS
FIGURE 65 INSTRUMENTATION LABORATORY COMPANY (WERFEN): SEGMENTAL REVENUE
FIGURE 66 INSTRUMENTATION LABORATORY COMPANY (WERFEN): REGIONAL REVENUE
FIGURE 67 EKF DIAGNOSTICS HOLDINGS PLC: KEY FINANCIALS
FIGURE 68 EKF DIAGNOSTICS HOLDINGS PLC: SEGMENTAL REVENUE
FIGURE 69 EKF DIAGNOSTICS HOLDINGS PLC: REGIONAL REVENUE
